<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antipsychotic dosing in children and adolescents with schizophrenia*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antipsychotic dosing in children and adolescents with schizophrenia*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Antipsychotic dosing in children and adolescents with schizophrenia*</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Medication</td> <td class="subtitle1">Initial dose</td> <td class="subtitle1">Recommended dose <span class="nowrap_whitespace">increase<sup>¶</sup></span></td> <td class="subtitle1">Therapeutic range</td> <td class="subtitle1">Max dose</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Second-generation antipsychotics</td> </tr> <tr> <td class="indent1" colspan="5">Aripiprazole<sup>[1]</sup></td> </tr> <tr> <td class="indent2">Preadolescent</td> <td>2 mg</td> <td>3 to 5 mg every three to five days (divided dose)</td> <td>5 to 20 mg</td> <td>20 mg</td> </tr> <tr> <td class="indent2">Adolescent</td> <td>2 mg</td> <td>3 to 5 mg every three to five days</td> <td>10 to 30 mg</td> <td>30 mg</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1" colspan="5">Lurasidone<sup>[2]</sup></td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent2">Preadolescent</td> <td>20 mg</td> <td>20 mg after one to three days</td> <td>20 to 40 mg</td> <td>40 mg</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent2">Adolescent</td> <td>40 mg</td> <td>40 mg after one to three days</td> <td>40 to 80 mg</td> <td>80 mg</td> </tr> <tr> <td class="indent1" colspan="5">Olanzapine<sup>[3]</sup></td> </tr> <tr> <td class="indent2">Preadolescent<sup>Δ</sup></td> <td>2.5 mg</td> <td>2.5 mg every three to five days (divided dose)</td> <td>5 to 20 mg</td> <td>20 mg</td> </tr> <tr> <td class="indent2">Adolescent<sup>Δ</sup></td> <td>5 mg</td> <td>5 mg every three to five days</td> <td>10 to 30 mg</td> <td>30 mg</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1" colspan="5">Paliperidone<sup>[4]</sup></td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent2">Preadolescent</td> <td>1.5 mg</td> <td>1.5 mg every five to seven days</td> <td>6 mg</td> <td>6 mg</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent2">Adolescent</td> <td>3 mg</td> <td>3 mg every five to seven days</td> <td>12 mg</td> <td>12 mg</td> </tr> <tr> <td class="indent1" colspan="5">Quetiapine<sup>[5]</sup></td> </tr> <tr> <td class="indent2">Preadolescent</td> <td>25 mg</td> <td>15 to 50 mg daily (divided twice daily or every eight hours)</td> <td>100 to 400 mg</td> <td>400 mg</td> </tr> <tr> <td class="indent2">Adolescent</td> <td>25 mg twice daily</td> <td>50 to 100 mg daily (divided twice daily or every eight hours)</td> <td>400 to 800 mg</td> <td>800 mg</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1" colspan="5">Risperidone<sup>[6-8]</sup></td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent2">Preadolescent</td> <td>0.25 mg</td> <td>0.25 to 0.5 mg increase every three to five days (divided dose)</td> <td>2 to 3 mg/day</td> <td>3 mg/day</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent2">Adolescent</td> <td>0.25 mg twice daily</td> <td>0.5 mg to 1 mg increase every three to five days (divided dose)</td> <td>3 to 6 mg/day</td> <td>6 mg/day</td> </tr> <tr> <td class="indent1" colspan="5">Clozapine<sup>[9,10]</sup></td> </tr> <tr> <td class="indent2">Preadolescent</td> <td>12.5 mg</td> <td>12.5 mg increase every three to five days (divided dose)</td> <td>150 to 900 mg</td> <td>900 mg</td> </tr> <tr class="divider_bottom"> <td class="indent2">Adolescent</td> <td>25 mg</td> <td>25 mg increase every three to five days</td> <td>150 to 900 mg</td> <td>900 mg</td> </tr> <tr> <td class="subtitle2_left" colspan="5">First-generation antipsychotics</td> </tr> <tr> <td class="indent1" colspan="5">Chlorpromazine</td> </tr> <tr> <td class="indent2">Preadolescent</td> <td>50 mg</td> <td>50 mg every one to three days (divided twice daily or every eight hours)</td> <td>50 to 400 mg</td> <td>400 mg/day</td> </tr> <tr> <td class="indent2">Adolescent</td> <td>100 mg</td> <td>50 to 100 mg every one to three days (divided twice daily or every eight hours)</td> <td>100 to 400 mg</td> <td>600 mg/day</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1" colspan="5">Haloperidol<sup>[11]</sup></td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent2">Preadolescent</td> <td>1 mg</td> <td>0.5 mg to 1 mg every three to five days</td> <td>0.5 to 6 mg</td> <td>10 mg</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent2">Adolescent</td> <td>1 mg</td> <td>1 mg every three to five days</td> <td>3 to 24 mg</td> <td>24 mg</td> </tr> <tr> <td class="indent1" colspan="5">Perphenazine<sup>[12]</sup></td> </tr> <tr> <td class="indent2">Preadolescent</td> <td>2 to 4 mg twice daily</td> <td>4 to 8 mg every three to five days (divided twice daily or every eight hours)</td> <td>16 to 36 mg/day</td> <td>36 mg/day</td> </tr> <tr> <td class="indent2">Adolescent</td> <td>4 to 8 mg three times daily</td> <td>4 to 8 mg every two to three days (divided twice daily or every eight hours)</td> <td>24 to 64 mg/day</td> <td>64 mg/day</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>* Weight, age, and exposure to previous antipsychotic medications should be taken into account when deciding upon dosing recommendations.</p>
<p>¶ If uncertain, we suggest starting with the lower dose and slower titration schedule.</p>
Δ Preadolescent is generally defined as school age up until age 12 and adolescent is age 13 to 17.</div><div class="graphic_reference">References:
<ol>
<li>Findling RL, Robb A, Nyilas M, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008; 165:1432.</li>
<li>Goldman R, Loebel A, Cucchiaro J, et al. Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study. J Child Adolesc Psychopharmacol 2017; 27:516.</li>
<li>Kryzhanovskaya L, Schulz C, McDougle CJ, et al. A double-blind, placebo-controlled study of olanzapine in adolescents with schizophrenia. Neuropsychopharmacology 2005; 30:S258.</li>
<li>Savitz AJ, Lane R, Nuamah I, et al. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: A randomized, double-blind study. J Am Acad Child Adolesc Psychiatry 2015; 54:126.</li>
<li>Shaw JA, Lewis JE, Pascal S, et al. A study of quetiapine: Efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 2001; 11:415.</li>
<li>McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347:314.</li>
<li>Haas M, Delbello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: A randomized, double-blind, placebo-controlled study. Bipolar Disord 2009; 11:687.</li>
<li>Haas M, Eerdekens M, Kushner S, et al. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: Double-blind study. Br J Psychiatry 2009; 194:158.</li>
<li>Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia: A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996; 53:1090.</li>
<li>Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006; 63:721.</li>
<li>Engelhardt DM, Polizos P, Waizer J, Hoffman SP. A double-blind comparison of fluphenazine and haloperidol in outpatient schizophrenic children . J Autism Dev Disord 1973; 3:128.</li>
<li>John M. Eisenberg Center for Clinical Decisions and Communications Science. First- and Second-Generation Antipsychotics for Children: Comparative Effectiveness. In: Comparative Effectiveness Review Summary Guides for Clinicians. Agency for Healthcare Research and Quality, Rockville 2007. Available from: https://www.ncbi.nlm.nih.gov/books/NBK109555/.</li>
</ol></div><div id="graphicVersion">Graphic 116251 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
